Study details
ELECTRA-SIRIO 2 is a clinical trial investigating antiplatelet treatment in patients with acute coronary syndrome (ACS). It focuses on ticagrelor and evaluates whether reducing its dose, with or without aspirin, can improve safety while maintaining effectiveness.
Title: Evaluation of safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in acute coronary syndrome: the randomized, multicentre, double-blind ELECTRA RCT study.
Principal Investigators:
prof. Jacek Kubica
prof. Eliano Pio Navarese
Study description
Recruitment status: Closed
Study phase: Phase 3
Simplified inclusion criteria:
• Signed informed consent; understands study and agrees to participate
• Age ≥ 18 years
• Able to follow study procedures and likely to complete the study
• Diagnosed with acute coronary syndrome (ACS): STEMI, NSTEMI, or unstable angina (UA)
Simplified exclusion criteria:
• Contraindication to ticagrelor or aspirin (ASA)
• Need for oral anticoagulation
• Advanced AV block (unless paced)
• Prior stent thrombosis on ticagrelor
• End-stage kidney disease (GFR <15 or dialysis)
• Planned revascularization after current hospitalization
• Poor compliance or cooperation
• Pregnancy